Arbutus Biopharma Corporation (ABUS)

[Slojab]

Arbutus Biopharma Corporation (NASDAQ: ABUS) At Current Prices: Is It Worth Investing In?

https://marketingsentinel.com/2021/10/15/arbutus-biopharma-corporation-nasdaq-abus-at-current-prices-is-it-worth-investing-in/

Linda Haig October 15, 2021 Technologies

During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)’s traded shares were 2.05 million, with the beta value of the company hitting 2.66. At the end of the trading day, the stock’s price was $4.15, reflecting an intraday loss of -0.24% or -$0.01. The 52-week high for the ABUS share is $5.87, that puts it down -41.45 from that peak though still a striking 41.45% gain since the share price plummeted to a 52-week low of $2.43. The company’s market capitalization is $428.28M, and the average intraday trading volume over the past 10 days was 3.76 million shares, and the average trade volume was 2.39 million shares over the past three months.

Arbutus Biopharma Corporation (ABUS) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.40. ABUS has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.24.

Arbutus Biopharma Corporation (NASDAQ:ABUS) trade information

Arbutus Biopharma Corporation (ABUS) registered a -0.24% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.24% in intraday trading to $4.15 this Thursday, 10/14/21, hitting a weekly high. The stock’s 5-day price performance is 1.22%, and it has moved by -1.66% in 30 days. Based on these gigs, the overall price performance for the year is 31.33%. The short interest in Arbutus Biopharma Corporation (NASDAQ:ABUS) is 4.15 million shares and it means that shorts have 3.13 day(s) to cover.

The consensus price target of analysts on Wall Street is $6.00, which implies an increase of 30.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $10.00 respectively. As a result, ABUS is trading at a discount of -140.96% off the target high and 3.61% off the low.

Arbutus Biopharma Corporation (ABUS) estimates and forecasts
Statistics show that Arbutus Biopharma Corporation has outperformed its competitors in share price, compared to the industry in which it operates. Arbutus Biopharma Corporation (ABUS) shares have gone up 35.18% during the last six months, with a year-to-date growth rate more than the industry average at 10.00% against 7.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 11.10% this quarter and then jump 4.30% in the quarter after that. In the rating firms’ projections, revenue will increase 38.40% compared to the previous financial year.

Revenue for the current quarter is expected to be $2.38 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $2.64 million by the end of Dec 2021.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.20%. While earnings are projected to return 65.40% in 2021.

ABUS Dividends

Arbutus Biopharma Corporation is due to release its next quarterly earnings between November 01 and November 05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Major holders

Arbutus Biopharma Corporation insiders own 19.15% of total outstanding shares while institutional holders control 31.66%, with the float percentage being 39.16%. RTW Investments LP is the largest shareholder of the company, while 119 institutions own stock in it. As of Jun 29, 2021, the company held over 5.98 million shares (or 6.03% of all shares), a total value of $18.11 million in shares.

The next largest institutional holding, with 5.84 million shares, is of Blackrock Inc.’s that is approximately 5.88% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $17.68 million.

Also, the Mutual Funds coming in first place with the largest holdings of Arbutus Biopharma Corporation (ABUS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.8 million shares. This amounts to just over 1.82 percent of the company’s overall shares, with a $5.99 million market value. The same data shows that the other fund manager holds slightly less at 1.79 million, or about 1.81% of the stock, which is worth about $5.42 million.